Shots:

• The approval is based on two clinical trials (P-III FINCH and P-II DARWIN) programs assessing Jyseleca in 3-500+ patients across a range of RA patient populations- including patients new to treatment and those who have demonstrated inadequate response to treatment with SOC including biologic DMARDs. Gilead and Eisai will jointly commercialize Jyseleca across Japan
• Results: improvement in clinical signs and symptoms- decreased disease activity and lessened the structural damage progression in their joints. Across the FINCH studies- Jyseleca demonstrated a consistent safety profile- and the frequency of AEs was comparable to control groups
• Jyseleca is a JAK1 inhibitor for the treatment of RA- in patients who have had an inadequate response to conventional therapies- including the prevention of structural joint damage

­ Ref: Gilead | Image : Gilead